Severe Mycoplasma pneumoniae Pneumonia During the 2023–2024 European Re-Emergence: Why Severity Does Not Predict Macrolide Resistance
Antibiotics · 21.05.2026 · 15 (5) · 524
DOI: 10.3390/antibiotics15050524 ↗Kurz gefasst
Fallbericht in der Zeitschrift Antibiotics, online erschienen am 21.05.2026. Verfasst von Enrico Perugini und 7 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, Department of System Medicine, Tor Vergata University, 00133 Rome, Italy. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health.
Abstract (Originalsprache)
Background
Following a significant decline during the 2020–2021 SARS-CoV-2 pandemic, Mycoplasma pneumoniae (MP) experienced a resurgence across Europe in 2023–2024. Although macrolide-resistant MP has increased globally, severe disease can occur even in the absence of resistance, which highlights the importance of rapid molecular characterization for clinical purposes. In this context, clinical severity is often improperly used as a surrogate marker of macrolide resistance, potentially driving unnecessary antibiotic escalation.
Methods
We report a severe MP pneumonia occurring during the 2023–2024 resurgence and evaluate macrolide resistance through a rapid two-step workflow (Real Time-PCR screening for A2063G/A2064G followed by confirmatory 23S rRNA sequencing), to assess whether severity predicts resistance and to support antibiotic stewardship.
Results
The patient developed acute hypoxic respiratory failure (PaO2 54.9 mmHg; P/F ratio 110), extensive centrilobular micronodules on chest CT imaging, significant systemic inflammation and elevated liver enzymes. Respiratory support was escalated from a Venturi mask to a high-flow nasal cannula and BiPAP. MP infection was confirmed by multiplex Real Time-PCR (RT-PCR) and supported by positive IgM/IgG serology. RT-PCR targeting A2063G/A2064G mutations revealed no resistance-associated variants, and Sanger sequencing of an 807 bp 23S rRNA fragment confirmed a wild-type genotype. Despite severe hypoxemic respiratory failure, no resistance-associated variants were detected, documenting a clear severity–genotype mismatch. Clinical and radiological improvement followed second-line antibiotic therapy.
Conclusions
Severe MP pneumonia can occur despite the absence of macrolide resistance. During MP re-emergence, clinical severity should not be used to infer macrolide resistance. Integrating nucleic acid amplification test (NAAT) diagnosis with rapid genotyping/confirmatory 23S rRNA sequencing can prevent misclassification, reduce unwarranted broad-spectrum escalation, and strengthen antimicrobial stewardship decisions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Infectious Diseases Unit, Department of System Medicine, Tor Vergata University, 00133 Rome, Italy.
- Department of Infectious Diseases, Galliera Hospital, 16128 Genoa, Italy.
- National Institute for Infectious Diseases "Lazzaro Spallanzani"-IRCCS, 00149 Rome, Italy.
- Department Experimental Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.
ORCID-Profile: Enrico Perugini, Marco Iannetta, Barbara Bartolini, Valentina Dimartino, Carla Fontana, Loredana Sarmati
Förderung
- Ministry of Health
Zitieren
APA
Perugini, E., Ferrari, L., Iannetta, M., Bartolini, B., Dimartino, V., Favaro, M., Fontana, C., & Sarmati, L. (2026). Severe Mycoplasma pneumoniae Pneumonia During the 2023–2024 European Re-Emergence: Why Severity Does Not Predict Macrolide Resistance. Antibiotics, 15(5), 524. https://doi.org/10.3390/antibiotics15050524
Vancouver
Perugini E, Ferrari L, Iannetta M, Bartolini B, Dimartino V, Favaro M, et al. Severe Mycoplasma pneumoniae Pneumonia During the 2023–2024 European Re-Emergence: Why Severity Does Not Predict Macrolide Resistance. Antibiotics. 2026;15(5):524. doi:10.3390/antibiotics15050524
BibTeX
@article{Perugini2026,
author = {Perugini, Enrico and Ferrari, Ludovica and Iannetta, Marco and Bartolini, Barbara and Dimartino, Valentina and Favaro, Marco and Fontana, Carla and Sarmati, Loredana},
title = {Severe Mycoplasma pneumoniae Pneumonia During the 2023–2024 European Re-Emergence: Why Severity Does Not Predict Macrolide Resistance},
journal = {Antibiotics},
year = {2026},
volume = {15},
number = {5},
pages = {524},
doi = {10.3390/antibiotics15050524}
}
EUVIMED